Becton Dickinson and Co vs IONQ Inc — how do they compare? Becton Dickinson and Co trades at $179.02 (market cap $49.41B), while IONQ Inc trades at $43.87 (market cap $17.60B). The key difference: Becton Dickinson and Co is far larger — about 2.8× IONQ Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| BDX | IONQ | |
|---|---|---|
Market Cap | $49.41B | $17.60B |
Sector | Health | Technology |
52-Week High | $185.39 | $82.09 |
52-Week Low | $138.62 | $26.59 |
Enterprise Value | $65.51B | $15.53B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
IONQ trades at $43.92, up 3.27% today, with a bullish technical signal and strong revenue growth of 287% in Q2 2026. Despite significant net losses and negative margins, the company's backlog surged to $485 million, and it secured a $28 million defense contract extension. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism about its quantum computing leadership.
Outlook: High growth potential in quantum computing with raised 2026 revenue guidance, but profitability remains distant. Risks include heavy cash burn, intense competition, and stock volatility. The stock offers speculative upside for growth investors tolerant of high risk.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →